November 16, 2026 The U.S. Food and Drug Administration (FDA) has issued a proposed rule that, if finalized, would deem N-acetyl-L-cysteine (NAC) “not excluded” from the definition of “dietary supplement” under federal law. This action follows an extended controversy regarding NAC, which the agency previously determined was precluded from use in dietary supplements due to its prior approval as a drug. This controversy culminated in two 2021 citizen petitions seeking a reversal of the FDA stance on NAC, which the American Herbal Products Association (AHPA) supported via formal docket comments. As a result of these same petitions, in 2022, FDA issued guidance describing the terms of an enforcement discretion policy under which the agency has continued to permit the sale of NAC products labeled as “dietary supplements.” Exercising a discretionary authority provided by section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the proposed rule would formally deem NAC “not excluded for use in or as a dietary supplement.” Today's action is the first use of this authority in the history of the FD&C Act. The rule would also codify that directly adding NAC to a dietary supplement is not a “prohibited act” under the federal law. AHPA continues to review the proposed rule in detail and intends to submit comments within the 60-day comment period announced in the Federal Register notice announcing the proposed rule. “Formal action from FDA to recognize the lawful status of NAC is welcome, and we appreciate the agency's utilizing of its statutory authority to resolve this uncertainty,” said AHPA President & CEO Graham Rigby. “However, the FD&C Act's drug preclusion provision remains fundamentally imbalanced, creating unnecessary unpredictability for responsible companies and limiting consumer access to safe dietary ingredients. Securing comprehensive legislative reform — such as the Dietary Supplement Innovation Act — and leveling the playing field for dietary supplements will be a priority for AHPA in 2027.”
Advocacy
AHPA advocates the U.S. Congress; state governments; FDA; FTC; USDA; FWS; NIH; NCCIH; U.S. Pharmacopeia and others for effective laws and regulations that promote the responsible commerce of herbal products.
News
AHPA informs members and the industry about news and issues through daily email alerts and a monthly newsletter. AHPA also promotes the benefits of herbs to mainstream and industry media as well as scientific journals.
Events
AHPA regularly produces in-person and online educational events featuring industry-leading experts discussing regulatory and technical issues that impact the herbal product industry.
Resource Library
AHPA provides guidance documents, policies, trade requirement, and reference materials to help members comply with the herbal industry laws and regulations.
Events
-
18Nov
AHPA Lunch & Learn - Rooted in Community: Traditional Medicinals
11:00 AM to 11:30 AM PST
-
2Dec
Get to Know AHPA: Utah
9:00 AM to 11:00 AM MST
-
2Dec
AHPA Lunch & Learn - AI at Work: Unleash Health
12:00 PM to 12:30 PM PST
-
3Dec
AHPA Webinar: Year-End Regulatory Update
10:00 AM to 11:30 AM PST
-
8Dec
AHPA Workshop: Microbiology Essentials for Botanicals & Dietary Supplements
12/8/2026 to 12/9/2026 EST
AHPA Annual Fund Sponsors
AHPA has no responsibility for any transaction entered into with any of these companies.


















